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Obesity and Cardiovascular Disease
Risk Factor, Paradox, and Impact of Weight Loss
Carl J. Lavie, MD, Richard V. Milani, MD, Hector O. Ventura, MD
New Orleans, Louisiana
Obesity has reached global epidemic proportions in both adults and children and is associated with numerous
comorbidities, including hypertension (HTN), type II diabetes mellitus, dyslipidemia, obstructive sleep apnea and
sleep-disordered breathing, certain cancers, and major cardiovascular (CV) diseases. Because of its maladaptive
effects on various CV risk factors and its adverse effects on CV structure and function, obesity has a major im-
pact on CV diseases, such as heart failure (HF), coronary heart disease (CHD), sudden cardiac death, and atrial
fibrillation, and is associated with reduced overall survival. Despite this adverse association, numerous studies
have documented an obesity paradox in which overweight and obese people with established CV disease, includ-
ing HTN, HF, CHD, and peripheral arterial disease, have a better prognosis compared with nonoverweight/
nonobese patients. This review summarizes the adverse effects of obesity on CV disease risk factors and its role
in the pathogenesis of various CV diseases, reviews the obesity paradox and potential explanations for these
puzzling data, and concludes with a discussion regarding the current state of weight reduction in the prevention
and treatment of CV diseases. (J Am Coll Cardiol 2009;53:1925–32) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.12.068w
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abesity has been increasing in epidemic proportions in both
dults and children (1,2). In adults, overweight is defined as
body mass index (BMI) 25 to 29.9 kg/m2 and obesity as
MI 30 kg/m2. Other indexes that have been used less
ommonly but possibly with more predictive power include
ody fatness, waist circumference (WC), waist-to-hip ratio
WHR), and weight-to-height ratio (3). A recent study of
early 360,000 participants from 9 European countries
howed that both general obesity and abdominal adiposity
re associated with risk of death and support the importance
f WC or WHR in addition to BMI for assessing mortality
isk (4).
Obesity has now become a critical problem in the U.S.,
ith the prevalence among adults increasing by nearly 50%
uring the 1980s and 1990s (5); now, nearly 70% of adults
re classified as overweight or obese compared with fewer
han 25% 40 years ago (5–7). Additionally, the distribution
f BMI in the U.S. has shifted in a skewed fashion such that
he proportion of the population with morbid obesity has
ncreased by a greater extent than overweight and mild
besity (1,2,5,7). Recent evidence indicates that obesity is
ssociated with more morbidity than smoking, alcoholism,
nd poverty, and if current trends continue, obesity may
oon overtake cigarette abuse as the leading cause of
reventable death in the U.S. (6–8). Should we fail to stop
he obesity epidemic, it has been predicted that we may soon
rom the Ochsner Medical Center, New Orleans, Louisiana.C
Manuscript received October 21, 2008; revised manuscript received December 2,
008, accepted December 9, 2008.itness an abrupt end, or even a reversal, of the steady
ncrease in life expectancy (3,9).
There are numerous adverse effects of obesity on general,
nd especially, cardiovascular (CV) health (Table 1) (6).
lthough obesity has been implicated as one of the major
isk factors for hypertension (HTN), heart failure (HF), and
oronary heart disease (CHD), evidence from clinical co-
orts of patients with established CV diseases indicates an
besity paradox because overweight and obese patients with
TN, HF, CHD, and peripheral arterial disease (PAD)
end to have a more favorable short- and long-term prog-
osis (Table 2).
This paper reviews the metabolic consequences of obesity
s well as its pathological effects on blood pressure and CV
tructure and function contributing to its role in HTN and
F as well as to its role in increasing CHD and atrial
brillation (AF). We also review the evidence for the obesity
aradox in these disorders as well as PAD. Finally, we
iscuss the current evidence for the potential risks and
enefits of purposeful weight loss.
athophysiology
he adipocyte acts as an endocrine organ, and plays a
ubstantial role in the pathogenesis and complications of
besity (1,10). Increased levels of leptin, an adipocyte-
erived hormone that controls food intake and energy
etabolism, may be particularly related with CV disease
nd has been reviewed in detail elsewhere (Fig. 1) (10,11).
-reactive protein (CRP) may play a role in the develop-
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Obesity and Heart Disease May 26, 2009:1925–32ment of leptin resistance, which
is important because endogenous
hyperleptinemia does not reduce
appetite or increase energy ex-
penditure (12).
Recently, increased concentra-
tions of both CRP and leptin
were associated with an increased
risk of major CV events, but
leptin seems to be a more robust
predictor (13). In a multivariate
model, leptin was an independent
predictor of CV events, whereas
CRP was not. Clearly, the increase
in inflammatory markers is associ-
ated with insulin resistance, obe-
sity, and CV events (11).
Effects of Obesity
on Hemodynamics and
CV Structure and Function
Obesity has many adverse effects
on hemodynamics and CV struc-
ture and function (Fig. 2) (14).
Obesity increases total blood vol-
ume and cardiac output, and car-
diac workload is greater in obe-
sity. Typically, obese patients
ave a higher cardiac output but a lower level of total
eripheral resistance at any given level of arterial pressure
14,15). Most of the increase in cardiac output with obesity
s caused by stroke volume, although because of increased
ympathetic activation, heart rate is typically mildly in-
reased as well (16). The Frank-Starling curve is often
hifted to the left because of increases in filling pressure
nd volume, thus increasing CV work. Obese patients are
ore likely to be hypertensive than lean patients, and
eight gain is typically associated with increases in arterial
ressure (15,16).
With increased filling pressure and volume, overweight
nd obese individuals often develop left ventricular (LV)
hamber dilation (14,16,17). Even independent of arterial
ressure and age, obesity increases the risk of left ventricular
ypertrophy (LVH), as well as other structural abnormali-
ies, including concentric remodeling (CR) and concentric
VH (18). In addition to LV structural abnormalities,
besity also leads to left atrial (LA) enlargement, both from
ncreased circulating blood volume as well as abnormal LV
iastolic filling (14,19). These abnormalities not only in-
rease the risk of HF, but LA enlargement may increase the
isk of AF and its morbid complications discussed later (20).
n addition to increasing LV structural abnormalities and
he propensity for more frequent and complex ventricular
rrhythmias (16), obesity also has adverse effects on diastolic
Abbreviations
and Acronyms
AF  atrial fibrillation
BMI  body mass index
CHD  coronary heart
disease
CR  concentric
remodeling
CRP  C-reactive protein
CV  cardiovascular
DM  diabetes mellitus
HF  heart failure
HTN  hypertension
LA  left atrial
LV  left ventricular
LVH  left ventricular
hypertrophy
MI  myocardial infarction
OSA  obstructive sleep
apnea
PAD  peripheral arterial
disease
SCD  sudden cardiac
death
WC  waist circumference
WHR  waist-to-hip rationd systolic function (14,19,21–23).
*
tlinical Consequences of Obesity
The art of simplicity is a puzzle of complexity.
—Doug Horton (1891–1968) (24)
besity, HTN, and the obesity paradox. Typically, HTN
eads to thickening of ventricular walls without chamber
ilation, a process referred to as CR when LV mass is not
ncreased or concentric LVH when LV mass is increased,
hereas obesity is characterized as increasing chamber
dverse Effects of Obesity
Table 1 Adverse Effects of Obesity
A. Increases in insulin resistance
1) Glucose intolerance
2) Metabolic syndrome
3) Type 2 diabetes mellitus
B. Hypertension
C. Dyslipidemia
1) Elevated total cholesterol
2) Elevated triglycerides
3) Elevated LDL cholesterol
4) Elevated non-HDL cholesterol
5) Elevated apolipoprotein-B
6) Elevated small, dense LDL particles
7) Decreased HDL cholesterol
8) Decreased apolipoprotein-A1
D. Abnormal left ventricular geometry
1) Concentric remodeling
2) Left ventricular hypertrophy
E. Endothelial dysfunction
F. Increased systemic inflammation and prothrombotic state
G. Systolic and diastolic dysfunction
H. Heart failure
I. Coronary heart disease
J. Atrial fibrillation
K. Obstructive sleep apnea/sleep-disordered breathing
L. Albuminuria
M. Osteoarthritis
N. Cancers
DL  high-density lipoprotein; LDL  low-density lipoprotein.
besity Paradox* inardiovascular and Noncardiovascular Patients
Table 2 Obesity Paradox* inCardiovascular and Noncardiovascular Patients
Cardiovascular
A. Hypertension
B. Heart failure
C. Coronary heart disease
1) Percutaneous revascularization
2) Coronary artery bypass graft surgery
3) Treadmill referrals
D. Peripheral arterial disease
E. Echocardiography referrals
Noncardiovascular
A. Elderly
B. End-stage renal disease and dialysis
C. Advanced cancers
D. Chronic obstructive lung disease
E. Rheumatoid arthritis
F. Human immunodeficiency virus/acquired immune deficiency syndromeConditions in which obesity has been associated with a more favorable prognosis compared with
hat in nonobese patients.
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May 26, 2009:1925–32 Obesity and Heart Diseaseilation without marked increases in wall thickness, a
rocess that leads to eccentric LVH (6,18).
Despite having a higher prevalence of HTN in obesity,
ecent data have shown an obesity paradox. Uretsky et al.
25) investigated the effects of obesity on CV outcomes in
2,576 treated hypertensive patients with known CHD.
uring 2-year follow up, all-cause mortality was 30% lower
n overweight and obese patients, despite less effective blood
ressure control in these patients compared with the normal
eight group. A previous study also showed decreased
troke risk and total mortality among overweight patients
ompared with lean patients (26). Similarly, another major
TN study showed a U-shaped relationship between all-
ause, CV, and non-CV mortality and BMI, meaning
xcess mortality at both extremes of BMI (27). In another
tudy of 800 elderly hypertensive patients, total mortality
nd CV and non-CV major events were highest in those
ith the leanest BMI quintile (28). The association between
MI and major CV events was U-shaped, whereas non-CV
ortality decreased with increasing BMI. In aggregate,
hese studies suggest that although obesity may be a
owerful risk factor for HTN and LVH, obese hypertensive
atients may paradoxically have a better prognosis, possibly
ecause of having lower systemic vascular resistance and
lasma renin activity compared with more lean hypertensive
atients (29).
besity, HF, and the obesity paradox. In a study of 5,881
ramingham Heart Study participants, Kenchaiah et al.
30) showed that during a 14-year follow-up, for every 1
g/m2 increment in BMI, the risk of HF increased 5% in
en and 7% in women. In fact, a graded increase in the risk
f HF was observed across all categories of BMI. In a study
f 74 morbidly obese patients, nearly one-third had
Figure 1 Overview of Leptin Resistance and Hyperleptinemia
in Obesity-Related Cardiovascular Disease
Reprinted, with permission, from Martin et al. (10).linical evidence of HF, and the probability of HFncreased dramatically with increasing duration of morbid
besity (23).
Despite the known adverse effects of obesity on both
ystolic and particularly diastolic CV function and the
pidemiologic data showing a strong link between obesity,
enerally defined by BMI criteria, and HF, many studies
ave suggested that obese HF patients had a better prog-
osis (Fig. 3) (31). In fact, we previously showed in a small
tudy of 209 patients with chronic systolic HF that both
igher BMI and percent body fat were independent predic-
ors of better event-free survival (Fig. 4) (32). Preliminary
ata in nearly 1,000 patients with systolic HF also showed
he prognostic impact of body fat on total survival (33).
In a recent meta-analysis of 9 observational HF studies
n  28,209) in which patients were followed up for an
verage of 2.7 years, Oreopoulos et al. (34) showed that
ompared with individuals without elevated BMI, over-
eight and obese HF patients had reductions in CV (19%
nd 40%, respectively) and all-cause (16% and 33%,
espectively) mortality. Likewise, in an analysis of BMI and
n-hospital mortality for 108,927 decompensated HF pa-
ients, higher BMI was associated with lower mortality (35).
n fact, for every 5-unit increase in BMI, the risk of
ortality was 10% lower (p  0.001).
Although these investigators raised the possibility that
election bias and baseline characteristics may have af-
ected these results, they also suggested that excess body
eight may confer some protective effects on HF mortality
Figure 2 Pathophysiology of Obesity and Cardiomyopathy
LV  left ventricular; RV  right ventricular.
Reprinted, with permission, from Alpert (14).
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Obesity and Heart Disease May 26, 2009:1925–3232–35). Because advanced HF is a catabolic state, obese
atients with HF may have more metabolic reserve (36–38).
ytokines and neuroendocrine profiles of obese patients also
ay be protective (34). Adipose tissue produces soluble
umor necrosis factor-alpha receptors and could play a
rotective role in obese patients with acute or chronic HF by
eutralizing the adverse biological effects of tumor necrosis
actor-alpha (39). Additionally, overweight and obese pa-
ients with acute and chronic HF have lower levels of
irculating atrial natriuretic peptides (40). Obese patients
ith HF may have attenuated sympathetic nervous system
nd renin-angiotensin responses (34). Because obese pa-
ients typically have high levels of arterial pressure, they may
ave a better prognosis in advanced HF and may tolerate
igher levels of cardioprotective medications (34). Higher
irculating lipoproteins in obese patients may bind and
etoxify lipopolysaccharides that play a role in stimulating
he release of inflammatory cytokines, all of which may serve
o protect the obese patient with HF (36,41). Unfortu-
ately, these studies do not typically adjust BMI for other
easures of adiposity (e.g., WC and WHR).
besity, CHD, and the obesity paradox. Obesity plays a
ajor role in adversely affecting major CHD risk factors,
ncluding HTN, dyslipidemia, and diabetes mellitus (DM),
s the major component of metabolic syndrome, and is
robably an independent risk factor for atherosclerosis and
HD events (6,29,42,43). Although recent studies indicate
hat the various measures to define obesity are not all created
qually regarding overall CV disease risk, the consensus is
hat compared with the traditional BMI assessments, the
ore refined modalities (e.g., WC, WHR, waist-to-height
atio, and so on) do not add significantly to the BMI assess-
ent from a clinical standpoint (3,44,45), although this has
ot been assessed for the obesity paradox. Therefore, however
easured, increasing obesity typically confers an increased
Figure 3
Risk-Adjusted Survival Curves for the 4 Body Mass
Index Categories at 5 Years in a Study of 1,203
Individuals With Moderate to Severe Heart Failure
Survival was significantly better in the overweight and obese
categories. Reprinted, with permission, from Horwich et al. (31).isk of CV diseases and CHD. Additionally, excess adipos-ty has been strongly related to first non–ST-segment
yocardial infarction (MI) occurring at a younger age (46).
Nevertheless, as with HTN and HF, many studies have
lso reported an obesity paradox in CHD, including in
atients treated with revascularization (6,47). In a recent
ystematic review of over 250,000 patients in 40 cohort
tudies followed up for 3.8 years, Romero-Corral et al. (47)
eported that overweight and obese CHD patients have a
ower risk for total and CV mortality compared with
nderweight and normal-weight CHD patients. However,
n patients with a BMI 35 kg/m2, there was an excess risk
or CV mortality without any increase in total mortality.
hese investigators explained the better outcomes for CV
nd total mortality in overweight and mildly obese CHD
roups, which could not be explained by confounding
actors, by implicating the lack of discriminatory power of
MI to differentiate between body fat and lean mass.
owever, data from our institution have shown the same
besity paradox when comparing patients with high and low
ercent body fat as with high and low BMI, although this
tudy did not assess WC, WHR, and other body composi-
Figure 4 Body Composition and Heart Failure Prognosis
Freedom from cardiovascular death or urgent transplantation in patients in
quintiles (Q) 1 and 5 for percent body fat (upper panel) and body mass index
(lower panel). Reprinted, with permission, from Lavie et al. (32).
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May 26, 2009:1925–32 Obesity and Heart Diseaseion parameters (48). Importantly, the obesity paradox has
lso been shown in patients after MI and revascularization,
nd more recently has been shown in patients referred for
xercise stress testing (47,49). Although the mechanism for
his effect is uncertain, in aggregate, these studies suggest
hat despite the fact that obesity increases the risk for
eveloping CHD, at least overweight and mild obesity do
ot seem to adversely affect prognosis in patients with
stablished CHD.
besity paradox in other CV populations. Galal et al.
50) have recently assessed 4.4-year mortality in 2,392
atients with PAD who had undergone major vascular
urgery and had high mortality risk during follow-up. This
tudy also showed a powerful obesity paradox, with progres-
ive reductions in mortality in normal BMI, overweight, and
bese groups compared with underweight patients. Al-
hough BMI was an independent predictor of greater
ortality in the entire cohort, a higher prevalence of
oderate-severe chronic obstructive pulmonary disease al-
ost completely explained the increased risk statistically in
he underweight patients. Nevertheless, adjusting for lung
isease did not abolish the relationship between higher BMI
nd lower mortality in the overweight and obese PAD
roups (50,51). Although many of the HTN, HF, and
HD studies discussed previously also attempted to correct
or smoking as a risk factor, lower BMI remained an
ndependent predictor of higher risk (51).
We have also documented the inverse relationship be-
ween BMI and all-cause mortality in over 30,000 patients
ith preserved LV systolic function referred for echocardi-
graphy (18). Like many studies, we found the highest
ortality in underweight patients, yet overweight, mildly
bese, and obese patients with BMI 35 kg/m2 had
ignificantly lower mortality than those with ideal BMI
18.5 to 25 kg/m2). Although overweight and obese patients
n our cohort had a higher prevalence of LV structural
bnormalities, including CR as well as both eccentric and
oncentric LVH, which were associated with increased
ortality, still higher BMI was independently associated
ith lower mortality. Nevertheless, when only examining
he obese patients with BMI 30 kg/m2, higher BMI was
ndependently associated with higher mortality, supporting
he idea that more marked obesity may still be associated
ith a worse prognosis.
besity and AF. As with obesity and the obesity-related
isorders, the prevalence of AF is increasing, and is expected
o increase 2.5-fold by 2050 (52). Although the increase in
F may be attributable to the aging of our population
ombined with the improved prognosis of HTN, CHD,
nd HF, conditions that increase the risk of AF, the
pidemic of obesity, with its attendant hemodynamic effects
nd impact on LV and LA structure and function, may also
ontribute to the higher prevalence of AF (20). Recently,
anahita et al. (52) reviewed 16 studies enrolling 123,000
atients to assess the impact of obesity on AF. In the
ubgroup of 5 population-based studies enrolling 78,602 vatients, obese patients had a nearly 50% increased risk of
eveloping AF that escalated with increasing BMI. On the
ther hand, post-cardiac surgery studies enrolling 44,647
atients failed to show an increased risk of AF in obesity.
besity and stroke. Numerous studies have reported an
ssociation between BMI and stroke (1). In fact, for each
-U increase in BMI, there was an increase of 4% in the risk
f ischemic stroke and 6% for hemorrhagic stroke (1,53).
his increased risk of stroke may be attributable to a higher
revalence of HTN, a prothrombotic/proinflammatory state
hat accompanies excess adipose tissue accumulation, as well
s increased AF.
Sudden death is more common in those who are
naturally fat than in the lean.
—Hippocrates (54)
besity and ventricular arrhythmias. Although progres-
ive HF may be the most common cause of death in patients
ith obesity cardiomyopathy, sudden cardiac death (SCD)
as been reported to be increased in apparently healthy
bese patients (1). Substantial evidence supports an in-
reased electrical irritability in obesity that may lead to more
requent and complex ventricular dysrhythmias (16), even in
he absence of LV dysfunction or clinical HF. In the
ramingham Heart Study (55), the annual SCD rate was
early 40 times higher than in a matched nonobese popu-
ation (16).
A positive association between corrected QT (QTc)
nterval and BMI has been noted, and prolonged QTc has
redicted increased mortality even in apparently healthy
opulations (56,57). Although a relationship between QTc
nd increased obesity has been noted in many studies, this is
ost evident in the severely obese (56,58). Likewise, in-
reased late potentials have also been linked to increased risk
f SCD, and the prevalence and number of abnormal
ate potentials has increased with more marked obesity (59).
he presence of late potentials may be related to some of
he pathological changes noted with cardiomyopathy of
besity (adipositas cordis), including myocyte hypertrophy,
brosis, and fat and mononuclear cell infiltration (1,14).
inally, obesity is associated with abnormalities in sym-
athovagal balance, leading to higher heart rate and reduced
eart rate variability, known factors related with increased
isk of SCD (2,11).
besity and sleep apnea. Obesity is a classic cause of
lveolar hypoventilation and the obstructive sleep apnea
OSA) syndrome (60). In fact, OSA may contribute to the
athogenesis of HTN and increased inflammation and CRP
61). Clearly, patients with OSA have increased risk of
TN, dysrhythmias, pulmonary HTN (present in 15% to
0% with OSA), HF, MI, stroke, and overall mortality (62).
besity and venous disease. The combination of in-
reased intravascular volume and high-volume lymphatic
verload, as well as reduced physical activity, often lead to
enous insufficiency and edema with increasing obesity (63).
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Obesity and Heart Disease May 26, 2009:1925–32dditionally, obesity is associated with an increased risk for
enous thromboembolism and pulmonary embolism, espe-
ially in women (64,65).
tatus of Weight Reduction
onsidering that some long-term studies have shown that
eight loss in overweight and obesity is associated with
ncreased mortality coupled with many CV studies showing
better prognosis with a higher BMI, it has been suggested
hat purposeful weight loss may not be beneficial and may
ven be detrimental in patients with CV diseases (31,66–68).
n contrast, however, other studies assessing mortality based
n body fat and lean mass rather than BMI or weight alone
ave suggested that subjects losing body fat rather than lean
ass have a lower mortality (67,69). Nevertheless, there are
otential adverse effects of weight loss. Certainly, starvation,
ery-low-calorie diets, liquid protein diets, and obesity
urgeries have been associated with prolongation of the QTc
nterval and increased risk of malignant dysrhythmias (1),
nd various pharmacologic agents have either limited effi-
acy or considerable toxicity (70–72).
Clearly lifestyle interventions, including exercise training
nd at least mild weight reduction with caloric restriction,
howed a nearly 60% reduction in the risk of developing
M, which was considerably better than that noted in
atients treated with metformin (73,74). The most studied
onpharmacologic therapy in CV disease for weight reduc-
ion has been cardiac rehabilitation and exercise training,
hich resulted in a 37% reduction in the prevalence of
etabolic syndrome (75). In a small subgroup of 45 obese
atients with 5% or more weight loss (average 10%) after
ardiac rehabilitation, we noted more significant improve-
ents in exercise capacity and plasma lipids than in 81
bese patients who did not lose weight (76). Recently, we
oted marked reductions after cardiac rehabilitation in CRP
evels in obese CHD patients, whereas lean patients had
nly slight and nonsignificant declines in CRP (77). In a
tudy of 530 patients, we noted marked improvements in
HD risk factors among overweight and obese CHD
atients who lost weight, including CRP, lipids, and glu-
ose, and this group had a trend of lower mortality (48).
ikewise, in a study of over 1,500 CHD patients, inten-
ional weight loss from a 6-month dietary program also
roduced a lower incidence of CHD events over 4 years
78). A recent study from the Mayo Clinic of 377 consec-
tive patients showed a benefit of weight loss on a compos-
te outcome (mortality plus major CV events), including
enefits noted in those with a BMI 25 kg/m2 as well as in
verweight and obese CHD patients (68). These studies
upport purposeful weight reduction in overweight and
bese CHD patients, despite the obesity paradox.
In HTN, weight reduction has resulted in significant
ecreases in arterial pressure (6,19). MacMahon et al. (79)
howed that even an 8-kg weight loss resulted in small but
tatistically greater reductions in LV wall thickness in mildlybese hypertensive patients compared with standard phar-
acologic intervention. In HF, despite the obesity paradox,
rials have suggested that weight loss can induce improve-
ents in LV mass as well as in systolic and diastolic
entricular function (14). In a study of 14 morbidly obese
atients who achieved marked weight loss (30% of body
eight) after gastroplasty, New York Heart Association
unctional class improved in 12 patients by an average of1
unctional class (23). Weight loss also was associated with
arked improvements in LV chamber size, LV end-systolic
all stress, and systolic and diastolic LV function.
Currently, many severely obese patients are being consid-
red for various obesity surgical procedures, and specialists
n CV diseases are increasingly being asked to evaluate and
lear these patients for anesthesia and surgery. Although
0-day mortality after gastric bypass has recently been
eported to be higher than expected, closely linked to
urgeon inexperience (80), more studies are now showing
hat these surgical procedures are associated with short- and
ong-term improvements in major morbidity and all-cause
ortality, particularly related with cancers, DM, and CV
iseases, and also predict long-term decreases in CV risk in
bese patients (81–85). Obesity surgery may reduce arterial
ressure over the short term (2 to 3 years), but may not have
long-term (e.g., 6 to 8 years) effect to reduce HTN
82,86). Large-scale studies are needed on the risks and
enefits of obesity surgeries in patients with advanced CV
iseases, including HTN, CHD, HF, and AF; a recent
mall study suggests that bariatric surgery is safe and
ffective in patients with severe systolic HF (87).
onclusions
verwhelming evidence supports the importance of obesity
n the pathogenesis and progression of CV disease. Al-
hough an obesity paradox exists, in that overweight and
bese patients with established CV diseases seem to have a
ore favorable prognosis than leaner patients, the constel-
ation of data still support purposeful weight reduction in
he prevention and treatment of CV diseases. Further
esearch is needed in all of these areas, and if the current
besity epidemic continues, we may soon witness an unfor-
unate end to the steady increase in life expectancy.
eprint requests and correspondence: Dr. Carl J. Lavie, Cardiac
ehabilitation, Exercise Laboratories, Ochsner Medical Center,
514 Jefferson Highway, New Orleans, Louisiana 70121-2483.
-mail: clavie@ochsner.org.
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